Clinical Trial

ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain

Study acronym: RENEU
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety and analgesic performance of the ReneuRx™ device in subjects with moderate to severe chronic lateral hip pain compared to subjects receiving treatment with corticosteroid injection in adults aged 22-80 years. Participants will attend study visits and complete quality of life questionnaires. Participants will be followed for approximately 6-12 months after the study procedure.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-05
notable Trial sites expanded: 0 -> 11 locations 2026-06-30
Trial Details
NCT Number NCT07568015
Lead Sponsor Brixton Biosciences, Inc.
Collaborators: MCRA
Conditions Greater Trochanteric Pain Syndrome, Greater Trochanteric Pain Syndrome of Both Lower Limbs, Lateral Hip Pain
Enrollment 100 participants
Start Date 2026-07-27
Primary Completion 2027-11-01 (estimated)
Study Completion 2029-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-04